Lumera pays Helix BioPharma $125,000
Canadian drugmaker Helix BioPharma has received a milestone payment of $125,000 from the USA's Lumera Corp under the terms of the license agreement they signed one year ago.
Lumera is currently developing a high-throughput, label-free detection platform in collaboration with the Seattle, USA-based Institute for Systems Biology, which may enable biologists to isolate protein samples for testing and analysis. The initial prototype device is currently undergoing testing and further development at the ISB.
Lumera is developing specialized microarrays, combining its exclusive license to Helix's Heterodimer Protein technology with its proprietary nanosurface modification chemistry, which Lumera believes will, for the first time, allow researchers to consistently take existing DNA arrays to produce protein arrays that accurately mimic the body's native living cell environment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze